TipRanks
Go Ultimate55% OFF

Compare Orphazyme (1TB0) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:1TB0OrphazymeEUR 80.00EUR 4.36M18.74-31.33%―Unlock the DE:1TB0 analyst price target with TipRanks PremiumDE:1TB0Unlock the DE:1TB0 top-analyst price target with TipRanks Premium
OZYMFOrphazyme$90.00$4.89M18.740.00%―Unlock the OZYMF analyst price target with TipRanks PremiumDE:1TB0 vs OZYMFUnlock the OZYMF top-analyst price target with TipRanks Premium
ACHVAchieve Life Sciences$6.83$702.82M-4.4130.34%Strong BuyUnlock the ACHV analyst price target with TipRanks PremiumDE:1TB0 vs ACHVUnlock the ACHV top-analyst price target with TipRanks Premium
AVTXAvalo Therapeutics$7.17$384.53M-1.51-60.24%Moderate BuyUnlock the AVTX analyst price target with TipRanks PremiumDE:1TB0 vs AVTXUnlock the AVTX top-analyst price target with TipRanks Premium
CRBPCorbus Pharmaceuticals$4.22$81.62M-0.65-74.33%Strong BuyUnlock the CRBP analyst price target with TipRanks PremiumDE:1TB0 vs CRBPUnlock the CRBP top-analyst price target with TipRanks Premium
GNPXGenprex$2.24$1.84M-0.01-98.38%―Unlock the GNPX analyst price target with TipRanks PremiumDE:1TB0 vs GNPXUnlock the GNPX top-analyst price target with TipRanks Premium
IRDOpus Genetics$3.67$305.33M-2.8986.29%Strong BuyUnlock the IRD analyst price target with TipRanks PremiumDE:1TB0 vs IRDUnlock the IRD top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:1TB0Orphazyme80.00-36.00-31.03%
OZYMFOrphazyme90.000.000.00%
ACHVAchieve Life Sciences6.831.7233.66%
AVTXAvalo Therapeutics7.17-9.50-56.99%
CRBPCorbus Pharmaceuticals4.22-8.08-65.69%
GNPXGenprex2.24-114.36-98.08%
IRDOpus Genetics3.671.5371.50%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts